Welcome to our dedicated page for Scientist Home Future Health SEC filings (Ticker: SHFH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Scientist Home Future Health's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Scientist Home Future Health's regulatory disclosures and financial reporting.
Scientist Home Future Health Limited, a Nevada holding company operating health supplement retail and check-up services in Hong Kong, reported for the six months ended June 30, 2026 revenue of $273,059, up from $76,376 a year earlier. Retail product sales contributed $265,156 and services $7,903.
The company posted a significantly larger net loss of $199,924 versus $31,154 in 2025, driven by higher selling, general and administrative expenses of $288,101. Cash fell to $9,047, with total assets of $529,844 and current liabilities of $340,299, resulting in net current liabilities of $214,975 and negative stockholders’ equity of $86,324.
Management and the auditor state that these losses, the working capital deficit and accumulated deficit raise substantial doubt about the company’s ability to continue as a going concern. Operations are funded by related‑party and director advances, and 100% of cost of revenues comes from a single related‑party vendor. Management also reports material weaknesses in internal control over financial reporting, including lack of segregation of duties and no independent board or audit committee.
Scientist Home Future Health Limited reported quarterly results for the three months ended March 31, 2026, showing rapid growth but rising losses. Revenue reached $188,756, mainly from retail sales of health supplements and topical creams, compared with $44,824 a year earlier. Higher salaries, rent, advertising, and professional fees pushed selling, general and administrative expenses to $161,140, leading to a net loss of $102,072 versus prior net income of $6,059. Cash fell to $15,332, total assets were $558,759, and stockholders’ equity declined to $11,427, close to the total liabilities of $547,332. Management and the auditor highlight substantial doubt about the company’s ability to continue as a going concern, citing recurring losses, net current liabilities of $120,220, dependence on related-party financing, and the need for additional shareholder support or external funding.
Scientist Home Future Health Limited reported its first full year of operations with 2025 revenue of $204,055, mainly from retail sales of health supplements and topical creams, plus physical check-up services. Despite this growth from 2024’s $120,775, the company posted a net loss of $231,725, reflecting high rental, professional and start-up operating expenses.
At December 31, 2025, cash was $68,888 against current liabilities of $214,458, resulting in net current liabilities of $22,212 and an accumulated deficit of $246,705. Both management and the auditor concluded these conditions raise substantial doubt about the company’s ability to continue as a going concern. The business relies heavily on related parties for product supply, office leases and funding, while the CEO controls about 84% of the 23,716,000 outstanding shares.
The stock is quoted on the OTC market under symbol SHFH and is likely to be treated as a penny stock, which may limit trading liquidity. Internal controls over financial reporting are described as ineffective due to lack of segregation of duties, absence of an independent board or audit committee, and missing formal control documentation.